About: Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 2008

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique (publié 2008) (fr) наукова стаття, опублікована в січні 2008 (uk) im Jahr 2008 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 2008 (ast) artikull shkencor i botuar më 01 janar 2008 (sq) scientific article published on 01 January 2008 (en)
publication date	wds:Q80543288-486A230F-0C71-4171-8E3C-131FDAF07EBA
publication date	2008-01-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q80543288-2FA1DBB4-4F15-4FD0-AEC3-7C21E8697772 wds:Q80543288-35FA2740-E6FF-4ADA-9C60-DF9AB0202EAE wds:Q80543288-6B6039D7-9DCE-4316-A8AD-FA0B1F3855CA wds:Q80543288-9CFF80B2-084A-4231-BBF2-B1EB043B8294 wds:Q80543288-AC164C57-1A21-485D-902D-2988338D959D wds:Q80543288-D452B40D-3C59-4DFA-AC4E-168963AF9B03 wds:Q80543288-E06FAD2D-0993-45FF-B934-D904C4C2DCD8 wds:Q80543288-E0B07B03-26D8-4605-882C-7C2C7A51D623 wds:Q80543288-FA5C84BD-70F9-4E01-988A-42A573EC8172
author name string	Thierry Lambert Roberto Musso Elena Santagostino Jørgen Ingerslev Jan van der Meer Albert Faradji Eduard Gorina KOGENATE Bayer European PMS Study Group Monika Maas-Enriquez
rdfs:label	Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (en) Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (nl) Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (sq)
skos:prefLabel	Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (en) Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (nl) Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (sq)
name	Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (en) Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (nl) Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (sq)
author	wds:Q80543288-55B86F66-98A4-4598-A944-B857E2193BAD
author	Alfonso Iorio
title	wds:Q80543288-DBC0F273-5167-49D0-BC22-0180EA8EBC8B
title	Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting (en)
page(s)	wds:Q80543288-8FF79F27-56DD-4E23-9909-812021DE0F9B
page(s)	52-58
instance of	wds:Q80543288-9A0BC07B-5942-48AE-A1AE-F6AD19420534
instance of	scholarly article
PubMed ID	wds:Q80543288-DEBAA408-401C-4D4D-84BE-A3A7DF6EF3E3
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18217134
PubMed ID	18217134
published in	wds:Q80543288-FCB52A1A-C6FD-421C-A6F1-F3FA0C54037E
published in	Thrombosis and Haemostasis
issue	wds:Q80543288-6CBC705A-7F66-4962-A3CF-63E3D713E655
volume	wds:Q80543288-D14E2E45-E525-4EE7-86B0-DA5F06A1D6ED
issue	1
volume	99
DOI	wds:Q80543288-34EE4DB3-E770-4361-8A38-F21F0600FD1C
DOI	http://dx.doi.org/10.1160/TH07-06-0409
DOI	10.1160/TH07-06-0409
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q80543288
is cites work of	Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance Recombinant factor VIII in the management of hemophilia A: current use and future promise Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A. Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
is cites work of	wds:Q34416394-77AA8835-01EC-4E99-ACB9-933127BF9DEF wds:Q35168244-F6CA6AF9-A7F2-4895-870C-5401E9185FFA wds:Q37230340-C8262DEC-B06E-4F4E-8321-11DEADF78BDA wds:Q37139733-096C1919-1D95-49EC-8023-5C9CD81BB733 wds:Q41917020-7CFBDDB1-5817-4CFE-A5B6-E381D4146892 wds:Q37625927-CA3DE8B8-8A7E-451D-AB0F-AD01817C6BB7 wds:Q36017537-0D1E2AD9-3C8C-4C47-83A0-86F047442265

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software